Search

CN-121971718-A - Rare earth anticoagulant material for venous line and preparation method and application thereof

CN121971718ACN 121971718 ACN121971718 ACN 121971718ACN-121971718-A

Abstract

The invention provides a rare earth anticoagulation material for venous pipelines and a preparation method and application thereof, wherein the rare earth anticoagulation material is prepared from raw materials comprising ferulic acid and rare earth nitrate, the ferulic acid is phenolic acid substance with antioxidation, anti-inflammation and antibiosis effects, the chemical property of rare earth ion is very similar to that of calcium ion, the rare earth ion has one positive charge more than that of calcium ion, the ion charge density is higher than that of calcium ion, the binding capacity to oxygen-containing ligand is stronger, the calcium can be replaced competitively, a more stable complex is formed, the protein structure is influenced, the normal coagulation process is destroyed, the anticoagulation effect is achieved, and the material with better anticoagulation effect can be obtained by combining the rare earth ion and the calcium ion.

Inventors

  • Sun Pizhi
  • ZHANG CHUNXIA
  • LIU GANG
  • CUI HONGLIANG
  • GUO PENGBO
  • Qiao Pengju
  • LI LU

Assignees

  • 天津包钢稀土研究院有限责任公司

Dates

Publication Date
20260505
Application Date
20260330

Claims (9)

  1. 1. A rare earth anticoagulation material for a venous line is characterized by being prepared from raw materials comprising ferulic acid, rare earth nitrate and other assistants, wherein the mass ratio of the ferulic acid to the rare earth nitrate is 1 (1-1.5), the rare earth nitrate comprises two or three of cerium nitrate hexahydrate, samarium nitrate hexahydrate and praseodymium nitrate hexahydrate, and the other assistants comprise hexamethylenetetramine, tannic acid and tea polyphenol.
  2. 2. The rare earth anticoagulant material for intravenous lines according to claim 1, wherein the rare earth nitrate comprises an essential component and an optional component, the essential component is cerium nitrate hexahydrate, the optional component is praseodymium nitrate hexahydrate and/or samarium nitrate hexahydrate, and the mass ratio of the essential component to the optional component is 1 (1-3).
  3. 3. The rare earth anticoagulant material for intravenous lines according to claim 1, wherein the mass ratio of hexamethylenetetramine to rare earth nitrate is 1 (1-2).
  4. 4. The rare earth anticoagulant material for intravenous lines according to claim 1, wherein the mass ratio of tannic acid to tea polyphenol is 1 (1-2), and the mass ratio of tannic acid to rare earth nitrate is 1 (10-12).
  5. 5. A process for preparing the rare-earth anticoagulation material for venous pipelines, as set forth in any one of claims 1-4, characterized in that the process comprises the steps of dissolving ferulic acid, hexamethylenetetramine and rare-earth nitrate in deionized water to obtain ferulic acid solution, hexamethylenetetramine solution and rare-earth nitrate solution, adding the hexamethylenetetramine solution into the ferulic acid solution to obtain reaction solution, keeping pH=7, slowly dripping the rare-earth nitrate solution into the reaction solution by adopting a gradient temperature control technology, adding tannic acid and tea polyphenol as auxiliary ligands to enhance anticoagulation activity, promoting coordination nucleus formation at 50-60 ℃ for 1-2 hours, heating to 70-80 ℃ for 3-4 hours, sequentially removing free small molecules by a dialysis membrane after the reaction, centrifuging and purifying by an ethanol/acetone mixed solvent, and finally obtaining the rare-earth anticoagulation material by freeze drying.
  6. 6. The method for preparing a rare earth anticoagulant material for a venous line according to claim 5, wherein the final concentration of the rare earth nitrate in the reaction solution is 100-120g/L.
  7. 7. The method for preparing a rare earth anticoagulant material for a venous line according to claim 5, wherein the dialysis membrane has a molecular weight cutoff of 2000Da and a volume ratio of ethanol to acetone is 1:1.
  8. 8. The use of the rare earth anticoagulant material for venous line according to any one of claims 1 to 4 in venous line coating, wherein the coating is prepared by sequentially pretreating a common PVC external venous line with ethanol, deionized water and polyethyleneimine solution, preparing 8 to 10g/L of rare earth anticoagulant material solution, and immersing the pretreated venous line in the rare earth anticoagulant material solution for 10 to 12 hours to obtain the venous line with anticoagulant coating.
  9. 9. The application of the rare earth anticoagulant material for the venous line on the venous line coating is characterized in that the pretreatment is specifically carried out by intercepting a section of common PVC external venous line, filling ethanol with the volume concentration of 95% into the inside of the line, sealing two ends by using hemostatic forceps, vibrating in a constant temperature shaking table for 1-2h at room temperature, pouring out the ethanol, washing by using deionized water, drying at 40-50 ℃, filling polyethylene imine solution with the mass concentration of 1% -2% into the inside of the line, sealing two ends by using hemostatic forceps, vibrating for 10-12h at room temperature in the constant temperature shaking table, and drying at 40-50 ℃ to complete the pretreatment of the common PVC external venous line.

Description

Rare earth anticoagulant material for venous line and preparation method and application thereof Technical Field The invention belongs to the field of anticoagulation materials, and particularly relates to a rare earth anticoagulation material for a venous pipeline, a preparation method and application thereof. Background The epicardial oxygenation (ECMO) is used as a core technology for rescuing critical cardiopulmonary failure patients, can partially or completely replace cardiopulmonary function, strives for time for the organ recovery of the patients, and is widely applied to the rescue of symptoms such as acute respiratory distress syndrome, cardiac arrest and the like. The ECMO system has its core components including membrane lung, blood pump and matching pipeline, and the direct contact between the pipeline and blood makes it easy to cause coagulation and form thrombus. Meanwhile, the pipeline needs to be frequently replaced after thrombus on the inner wall of the pipeline is formed. At present, the surface modification strategy for ECMO pipeline in the prior art can not effectively solve the core problem of coagulation. The blood coagulation process is closely related to calcium ions, and the rare earth ions can competitively inhibit the action of the calcium ions due to the similarity of the properties of the rare earth ions with the calcium ions, so that the coagulation process is destroyed. In recent years, the combination of compounds with drug effects and metal ions to enhance the drug efficacy becomes an important direction for the development of novel drugs, and provides a new idea and method for the development of anticoagulation medical instruments. Disclosure of Invention In view of the above, the present invention aims to provide a rare earth anticoagulant material for a venous line, a preparation method and an application thereof, wherein the anticoagulant material having an anticoagulant effect on blood is prepared from rare earth compounds, ferulic acid and other raw materials, and the anticoagulant material is loaded on the inner wall of a venous line by an ion bond combination dipping method to form an anticoagulant coating, and the venous line with the anticoagulant coating can effectively prevent blood from being coagulated in an extracorporeal circulation process. In order to achieve the above purpose, the technical scheme of the invention is realized as follows: The rare earth anticoagulation material for the venous line is prepared from raw materials comprising ferulic acid, rare earth nitrate and other additives, wherein the mass ratio of the ferulic acid to the rare earth nitrate is 1 (1-1.5), the rare earth nitrate comprises two or three of cerium nitrate hexahydrate, samarium nitrate hexahydrate and praseodymium nitrate hexahydrate, and the other additives comprise hexamethylenetetramine, tannic acid and tea polyphenol. The rare earth elements can be combined with biomacromolecule proteins, can also be combined with nucleic acids and substances forming structural units such as amino acids, nucleotides and the like to form complexes, thereby participating in or interfering with the processes such as substance metabolism and biosynthesis of cells in organisms. Since rare earth ions have many similarities to calcium ions, such as the ionic radius of rare earth is similar to that of calcium ions, which play an indispensable role in the coagulation process, rare earth is often used as a calcium antagonist or substituted in organisms to interfere with the normal physiological functions of calcium ions. The rare earth ion has larger adaptability to coordination space structures with different coordination numbers, the rare earth ion has one positive charge more than calcium, the ion charge density is higher than that of calcium ion, the binding capacity to oxygen-containing ligands is stronger, and the rare earth ion can competitively replace calcium, because of the special property of the rare earth ion, the rare earth ion with high charge density can replace calcium ions to form a more stable compound in the coagulation process, the normal conformation of protein is damaged, the complete molecular structure of the protein is further influenced, the normal coagulation process is damaged, and the anticoagulation effect is realized. Further, the rare earth nitrate comprises necessary components and optional components, wherein the necessary components are cerium nitrate hexahydrate, the optional components are praseodymium nitrate hexahydrate and/or samarium nitrate hexahydrate, and the mass ratio of the necessary components to the optional components is (1-3). Further, the mass ratio of the hexamethylenetetramine to the rare earth nitrate is 1 (1-2). Further, the mass ratio of tannic acid to tea polyphenol is 1 (1-2), and the mass ratio of tannic acid to rare earth nitrate is 1 (10-12). The invention also provides a preparation method of the rare earth anticoagulant material for t